Open AccessSODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS AS NEW STRATEGY OF CHRONIC HEART FAILURE MANAGEMENT
Author(s) -
A.S. Herashchenko,
Sergiy Fedorov
Publication year - 2020
Publication title -
emergency medical service
Language(s) - English
Resource type - Journals
ISSN - 2391-7822
DOI - 10.36740/emems202003109
Subject(s) - empagliflozin , medicine , heart failure , diabetes mellitus , intensive care medicine , benzhydryl compounds , clinical trial , cotransporter , canagliflozin , cardiology , type 2 diabetes mellitus , endocrinology , sodium , chemistry , organic chemistry , bisphenol a , epoxy
Heart failure (HF) affects over 26 million people worldwide and is associated with high morbidity andmortality. Diabetes mellitus (DM) is a common cause of HF in current clinical practice. In recent years, the prevalenceof DM has increased considerably, with an estimated 439 million adults worldwide projected to be affected by the year2030. The aim: To was evaluate of modern trials in patients with diabetes and heart failure treated by Sodium-glucosecotransporter-2 inhibitors.Materials and Methods: The database from PubMed for the last 10 years has been reviewed.Conclusion: SGLT2i, namely Empagliflozin, has good results in their recovery from patients with HFrEF, but the resultsof their use in patients with HFpEF are currently questionable and need further study.